NDC product
Besponsa
NDC 0008-0100 · Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Key facts
| Product NDC | 0008-0100 |
|---|---|
| Proprietary name | Besponsa |
| Nonproprietary name | inotuzumab ozogamicin |
| Substances | INOTUZUMAB OZOGAMICIN |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761040 |
| Pharmacologic classes | CD22-directed Antibody Interactions [MoA], CD22-directed Immunoconjugate [EPC], Decreased DNA Integrity [PE], Immunoconjugates [CS], Increased Cellular Death [PE] |
| Marketing start | Aug 18, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: